a b s t r a c t Intravenous (i.v.) bisphosphonates relieve pain in conditions such as Paget's disease of bone, metastatic bone disease, and multiple myeloma. Based on positive findings from a prior case series, we conducted a randomized placebo-controlled study to assess the analgesic effect of i.v. pamidronate in subjects with chronic low back pain (CLBP) and evidence of degenerative disease of the spine. Four groups of 11 subjects (7 active, 4 placebo) were enrolled at escalating dose levels of 30, 60, 90, and 180 mg pamidronate (the latter administered as two 90 mg infusions). Primary outcomes were safety and change from baseline in average daily pain scores, recorded at 1, 2, 3, and 6 months postinfusion using electronic diaries. Secondary outcomes included responder rate, daily worst pain, and pain-related interference with daily function. There were no pamidronate-related serious adverse events or other significant safety findings. A statistically significant overall treatment difference in pain scores was observed, with clinically meaningful effects persisting for 6 months in the 180 mg pamidronate group. Least squares mean changes in daily average pain score were À1.39 (SE = 0.43) for placebo, and À1.53 (0.71), À1.26 (0.81), À1.42 (0.65), and À4.13 (0.65) for pamidronate 30, 60, 90, and 180 mg, respectively (P = 0.012 for pamidronate 180 mg vs placebo). The proportion of responders, changes in worst pain, and pain interference with daily function were also significantly improved for pamidronate 180 mg compared with placebo. In conclusion, i.v. pamidronate, administered as two 90 mg infusions, decreased pain intensity for 6 months in subjects with CLBP. Ó
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Introduction
Chronic low back pain (CLBP) is a widespread disorder affecting men and women of nearly all ages [3, 9] . The lifetime prevalence of CLBP is reported to be between 54% and 80%, with an annual prevalence between 15% and 45% and a point prevalence ranging from 12% to 30% [19, 34] . The prevalence of CLBP appears to be increasing: a survey of North Carolina households found an increase in disabling CLBP from 3.9% in 1992 to 10.2% in 2006, distributed across all adult ages and races [19] . Persistent pain and disability due to CLBP contribute to significant social and economic health burdens; CLBP is the number one cause of disability in persons aged <45 years and one of the most expensive nonfatal medical conditions in industrialized countries [3, 34] .
Based on imaging studies, the majority of patients with CLBP present with variable evidence of spondylotic disease, degenerative disk disease or facet joint arthritis. However, imaging studies are mechanistically nonspecific and findings correlate poorly with both the occurrence and severity of low back pain. Therefore, in the absence of findings of a specific spinal or extraspinal pathology, the term ''nonspecific'' is sometimes added to the diagnosis of low back pain [11] . A number of pharmacological, interventional, surgical, and rehabilitative treatment approaches are currently available for CLBP; however, despite the variety of treatments, most patients experience only short-term or unsatisfactory pain relief [11] .
Bisphosphonates are known to have significant analgesic activity in addition to their well-characterized role in inhibiting bone resorption. For example, pamidronate (Aredia 
